Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractEvidence for an association between selenium status and prostate cancer risk is still inconclusive. Anticarcinogenic effects of selenium are supposedly mediated through cellular protective and redox properties of selenoenzymes in vivo. We evaluated the association between serum selenium status and prostate cancer risk in a population with relative low selenium concentrations considering effect modification by genetic variants in selenoprotein genes.
A case-control study of 248 incident prostate cancer cases and 492 matched controls was nested within the EPIC-Heidelberg cohort. Baseline blood samples were analyzed for serum selenium and selenoprotein P concentrations and glutathione peroxidase activity. Genotyping was carried out for SEP15 (rs5859, rs540049), SEPP1 (rs3877899, rs7579), GPX1 (rs1050450), and GPX4 (rs713041). Conditional logistic regression was used to calculate adjusted odds ratios (OR) and 95% confidence intervals (95% CI).
The OR for prostate cancer was 0.89 (95% CI, 0.79-1.01) per 10 μg/L increase of serum selenium concentration. This association was modified by rs1050450 (C>T) in GPX1 (P(interaction) = 0.03), with carriers of one or two T alleles having a significantly reduced OR of 0.87 (95% CI, 0.76-0.99). Furthermore, there was an association between rs7579 genotype in SEPP1 and prostate cancer risk (OR, 1.72; 95% CI, 0.99-2.98).
Our results support a role of selenium and polymorphisms in selenoenzymes in prostate cancer etiology, which warrants confirmation in future studies.
These findings might help to explain biological effects of selenium in prostate cancer development in order to overcome inconsistencies arising from former studies.
CitationCancer Epidemiol. Biomarkers Prev. 2010, 19 (11):2958-2968
SponsorsThe following authors have membership on EU NoE, which was instrumental in the initiation of the study: J. Linseisen, S. Rohrmann (ECNIS), J. Hesketh (NuGO), and B. Åkesson (NuGO, ECNIS).
- Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis.
- Authors: Xie W, Yang M, Chan J, Sun T, Mucci LA, Penney KL, Lee GS, Kantoff PW
- Issue date: 2016 May
- A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival.
- Authors: Penney KL, Schumacher FR, Li H, Kraft P, Morris JS, Kurth T, Mucci LA, Hunter DJ, Kantoff PW, Stampfer MJ, Ma J
- Issue date: 2010 May
- Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans.
- Authors: Zheng SL, Sun J, Cheng Y, Li G, Hsu FC, Zhu Y, Chang BL, Liu W, Kim JW, Turner AR, Gielzak M, Yan G, Isaacs SD, Wiley KE, Sauvageot J, Chen HS, Gurganus R, Mangold LA, Trock BJ, Gronberg H, Duggan D, Carpten JD, Partin AW, Walsh PC, Xu J, Isaacs WB
- Issue date: 2007 Oct 17
- The influence of selenium and selenoprotein gene variants on colorectal cancer risk.
- Authors: Méplan C, Hesketh J
- Issue date: 2012 Mar
- Genetic variants in selenoprotein genes increase risk of colorectal cancer.
- Authors: Méplan C, Hughes DJ, Pardini B, Naccarati A, Soucek P, Vodickova L, Hlavatá I, Vrána D, Vodicka P, Hesketh JE
- Issue date: 2010 Jun